pills), a compounding pharmacy can modify the ingredients or delivery method
The FDA has additionally greenlit biweekly dosing of the SCIg therapy, backed by a Phase IV trial that showed non-inferiority in total Ig levels compared to weekly administration
Notable findings include: In the SURMOUNT-1 trial of tirzepatide for the treatment of obesity, secondary findings showed improvements in the GLP-1 treatment group in systolic blood pressure (-7.2mm Hg), diastolic blood pressure (-4.8mm Hg), triglycerides (-24.8mg/dl), fasting insulin (-42.9mIU liter), and total cholesterol (-4.8mg/dl)
Proactive Rehydration: Hydration on GLP-1 therapy requires an intentional schedule rather than relying exclusively on the sensation of thirst
An Informational Analysis of TrimRx Compounded Semaglutide and Tirzepatide Programs, Telehealth Prescription Process, Published Pricing Disclosures, Pharmacy Partnerships and Patient Safety Information for 2026 San Diego, California, March 09, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only and does not constitute medical advice
